Fulcrum Capital LLC Has $599,000 Stock Position in Johnson & Johnson (NYSE:JNJ)

Fulcrum Capital LLC lifted its stake in Johnson & Johnson (NYSE:JNJ) by 2.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,698 shares of the company’s stock after buying an additional 96 shares during the period. Fulcrum Capital LLC’s holdings in Johnson & Johnson were worth $599,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the stock. Wallington Asset Management LLC raised its holdings in shares of Johnson & Johnson by 3.4% in the 3rd quarter. Wallington Asset Management LLC now owns 88,324 shares of the company’s stock worth $14,314,000 after buying an additional 2,889 shares in the last quarter. Eagle Bay Advisors LLC raised its holdings in shares of Johnson & Johnson by 2.3% in the 3rd quarter. Eagle Bay Advisors LLC now owns 5,042 shares of the company’s stock worth $817,000 after buying an additional 114 shares in the last quarter. Iron Horse Wealth Management LLC grew its position in Johnson & Johnson by 55.9% during the 3rd quarter. Iron Horse Wealth Management LLC now owns 2,474 shares of the company’s stock worth $401,000 after acquiring an additional 887 shares during the last quarter. Detalus Advisors LLC grew its position in Johnson & Johnson by 6.0% during the 3rd quarter. Detalus Advisors LLC now owns 4,907 shares of the company’s stock worth $795,000 after acquiring an additional 277 shares during the last quarter. Finally, Coston McIsaac & Partners grew its position in Johnson & Johnson by 2.5% during the 3rd quarter. Coston McIsaac & Partners now owns 37,483 shares of the company’s stock worth $6,074,000 after acquiring an additional 924 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the sale, the vice president now owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 0.16% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms recently commented on JNJ. Wells Fargo & Company increased their price target on Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 16th. TD Cowen decreased their price target on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a research report on Thursday, July 18th. Daiwa Capital Markets lowered Johnson & Johnson from an “outperform” rating to a “neutral” rating and decreased their price target for the stock from $160.00 to $150.00 in a research report on Tuesday, July 23rd. Citigroup increased their price objective on Johnson & Johnson from $180.00 to $185.00 and gave the company a “buy” rating in a research report on Wednesday, October 16th. Finally, Daiwa America lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. Six analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $175.93.

Johnson & Johnson Stock Down 1.3 %

NYSE:JNJ opened at $163.67 on Friday. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $168.85. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $393.90 billion, a P/E ratio of 10.20, a P/E/G ratio of 2.65 and a beta of 0.52. The stock’s fifty day simple moving average is $163.29 and its 200-day simple moving average is $154.92.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The business had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. During the same period last year, the company earned $2.66 EPS. The firm’s revenue was up 5.2% on a year-over-year basis. Equities research analysts expect that Johnson & Johnson will post 10 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be paid a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.03%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson’s payout ratio is presently 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.